The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved June 1998

Specific Treatments:

pulmonary tuberculosis

Therapeutic Areas

General Information

Priftin has been approved for the treatment of pulmonary tuberculosis. Priftin must always be used in conjunction with at least one other antituberculosis drug to which Mycobacterium tuberculosis is susceptible. Priftin should be administered twice weekly for two months, with an interval of no less than three days (72 hours) between doses, as part of an appropriate regimen which includes companion drugs.

Side Effects

The most common adverse events related to treatment with Priftin combination therapy include hyperuricemia, increased liver function tests, neutropenia, pyuria, proteinuria, and lymphopenia.